ArticleJAMA oncology2017
Overall Survival in Cancer Drug Trials as a New Surrogate End Point for Overall Survival in the Real World.
Article in JAMA oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Optimal early endpoint for second-line or subsequent immune checkpoint inhibitors in previously treated advanced solid cancers: a systematic review.BMC cancer · 2025Pooled it
- Current challenges in screening for pancreatic ductal adenocarcinoma: an appraisal of the METAPAC study.Translational gastroenterology and hepatology · 2026Article
- Curative intent therapy of stage I-III non-small cell lung cancer: a patient-centered precision approach to assess, measure, and interpret benefits and harms.Journal of thoracic disease · 2025Article
- Article
- Article
- Real-world data: bridging the gap between clinical trials and practice.EClinicalMedicine · 2024Review
- Merkel Cell Carcinoma: Integrating Epidemiology, Immunology, and Therapeutic Updates.American journal of clinical dermatology · 2024Review
- Article
- Expanding treatment options for patients with HER2+ metastatic breast cancer with margetuximab plus chemotherapy: a case report series.Frontiers in oncology · 2024Article
- Bedside implications of the use of surrogate endpoints in solid and haematological cancers: implications for our reliance on PFS, DFS, ORR, MRD and more.BMJ oncology · 2024Review
- Real world data on IO-based therapy for metastatic renal cell carcinoma.Journal of cancer research and clinical oncology · 2023Article
- Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective study.Cell reports. Medicine · 2022Article
- Decision Making in Older Adults With Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Review
- Real-World Survival Outcomes Associated With First-Line Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Clear Cell Renal Cell Carcinoma.JAMA network open · 2021Article
- Pragmatic trials with prespecified subgroups: what oncologists can learn from COVID-19.Nature reviews. Clinical oncology · 2021Article
- Use of record linkage to evaluate treatment outcomes and trial eligibility in a real-world metastatic prostate cancer population in Scotland.Pharmacoepidemiology and drug safety · 2020Observational
- Real-World Evidence in Oncology: Opportunities and Limitations.The oncologist · 2020Article
- Use of targeted therapies for advanced renal cell carcinoma in the Veterans Health Administration.Cancer medicine · 2019Article
- Article
- Cancer drug development: The missing links.Experimental biology and medicine (Maywood, N.J.) · 2019Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
27892992What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.